Sarah Barelier
Affiliations: | 2013- | Chemistry | University of California, San Francisco, San Francisco, CA |
Google:
"Sarah Barelier"Mean distance: 9.91 | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barelier S, Sterling T, O'Meara MJ, et al. (2015) The Recognition of Identical Ligands by Unrelated Proteins. Acs Chemical Biology |
| Barelier S, Eidam O, Fish I, et al. (2014) Increasing chemical space coverage by combining empirical and computational fragment screens. Acs Chemical Biology. 9: 1528-35 |
| Barelier S, Cummings JA, Rauwerdink AM, et al. (2014) Substrate deconstruction and the nonadditivity of enzyme recognition. Journal of the American Chemical Society. 136: 7374-82 |
| Barelier S, Boyce SE, Fish I, et al. (2013) Roles for ordered and bulk solvent in ligand recognition and docking in two related cavities. Plos One. 8: e69153 |
| Eidam O, Romagnoli C, Dalmasso G, et al. (2012) Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo. Proceedings of the National Academy of Sciences of the United States of America. 109: 17448-53 |
| Barelier S, Krimm I. (2011) Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Current Opinion in Chemical Biology. 15: 469-74 |
| Barelier S, Pons J, Gehring K, et al. (2010) Ligand specificity in fragment-based drug design. Journal of Medicinal Chemistry. 53: 5256-66 |
| Barelier S, Linard D, Pons J, et al. (2010) Discovery of fragment molecules that bind the human peroxiredoxin 5 active site. Plos One. 5: e9744 |
| Barelier S, Pons J, Marcillat O, et al. (2010) Fragment-based deconstruction of Bcl-xL inhibitors. Journal of Medicinal Chemistry. 53: 2577-88 |